Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?

Published on Sep 1, 2019in Metabolism-clinical and Experimental6.513
路 DOI :10.1016/j.metabol.2019.07.009
Niki Katsiki (BIDMC: Beth Israel Deaconess Medical Center), Nikolaos Perakakis9
Estimated H-index: 9
(BIDMC: Beth Israel Deaconess Medical Center),
Christos S. Mantzoros106
Estimated H-index: 106
(BIDMC: Beth Israel Deaconess Medical Center)
  • References (77)
  • Citations (0)
馃摉 Papers frequently viewed together
6 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Lee-Lee Lai (UM: University of Malaya)H-Index: 3
#2Shireene Ratna Vethakkan (UM: University of Malaya)H-Index: 7
Last. Wah-Kheong Chan (UM: University of Malaya)H-Index: 13
view all 5 authors...
Background and Aims Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of drugs that lower glucose by inducing renal glycosuria. We aimed to explore whether SGLT2 inhibitor added to the usual care for patients with type 2 diabetes mellitus (T2DM) and biopsy-proven nonalcoholic steatohepatitis (NASH) will benefit NASH histology.
5 CitationsSource
#1Dimitrios A. Koutoukidis (NIHR: National Institute for Health Research)H-Index: 4
#2Nerys M. Astbury (NIHR: National Institute for Health Research)H-Index: 13
Last. Paul Aveyard (NIHR: National Institute for Health Research)H-Index: 47
view all 8 authors...
漏 2019 American Chemical Society. All rights reserved. Importance: Nonalcoholic fatty liver disease (NAFLD) affects about 25% of adults worldwide and is associated with obesity. Weight loss may improve biomarkers of liver disease, but its implications have not been systematically reviewed and quantified. Objective: To estimate the association of weight loss interventions with biomarkers of liver disease in NAFLD. Data Sources: MEDLINE, Embase, PsycINFO, CINAHL, Cochrane, and Web of Science datab...
4 CitationsSource
#1Ofri Mosenzon (HUJI: Hebrew University of Jerusalem)H-Index: 21
#2Stephen D. Wiviott (Brigham and Women's Hospital)H-Index: 67
Last. Itamar Raz (HUJI: Hebrew University of Jerusalem)H-Index: 49
view all 21 authors...
Summary Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular disease. Here we report analyses of renal outcomes with the SGLT2 inhibitor dapagliflozin in the DECLARE鈥揟IMI 58 cardiovascular outcomes trial, which included patients with type 2 diabetes both with and without established atherosclerotic cardiovascular disease and mostly with preserved renal function. Methods In ...
28 CitationsSource
#1Gert MayerH-Index: 33
#2Christoph WannerH-Index: 76
Last. David Z.I. Cherney (U of T: University of Toronto)H-Index: 31
view all 9 authors...
In patients with type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease, empagliflozin (EMPA) decreased progression of chronic kidney disease (CKD), likely via a reduction in intraglomerular pressure. Due to prevalent comorbidities, such as hypertension and albuminuria, patients often receive other agents that alter intrarenal hemodynamics, including angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs), calcium channel blockers (CCBs) and diuretics. Nonster...
5 CitationsSource
#1Stergios A. Polyzos (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 32
#2Nikolaos Perakakis (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 9
Last. Christos S. Mantzoros (Harvard University)H-Index: 106
view all 3 authors...
Abstract Lipodystrophy is a group of clinically heterogeneous, inherited or acquired, disorders characterized by complete or partial absence of subcutaneous adipose tissue that may occur simultaneously with the pathological, ectopic, accumulation of fat in other regions of the body, including the liver. Fatty liver adds significantly to hepatic and extra-hepatic morbidity in patients with lipodystrophy. Lipodystrophy is strongly associated with severe insulin resistance and related comorbidities...
3 CitationsSource
#1Mitsuko Inoue (Kitasato University)H-Index: 1
#2Akinori Hayashi (Kitasato University)H-Index: 6
Last. Masayoshi Shichiri (Kitasato University)H-Index: 46
view all 8 authors...
6 CitationsSource
#1Niki Katsiki (AHEPA University Hospital)H-Index: 4
#2George Dimitriadis (UoA: National and Kapodistrian University of Athens)H-Index: 29
Last. Christos S. Mantzoros (Harvard University)H-Index: 106
view all 10 authors...
Abstract Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are oral antidiabetic agents that exert their glucose-lowering effect by increasing renal excretion of glucose. These drugs have been reported to beneficially affect cardiovascular (CV) and renal outcomes. However, concerns have recently been raised in relation to increased risk of lower-extremities amputation with canagliflozin and it remains unclear whether and to what extent this side effect could also occur with other SGLT2i. The p...
3 CitationsSource
Purpose of the Review Hyperactivity of sympathetic nervous system (SNS) plays a role in the development of arterial hypertension and heart failure, two co-morbidities frequently associated with type 2 diabetes (T2DM). This review aims at analyzing the effects of sodium-glucose cotransporter type 2 inhibitors (SGLT2is) on blood pressure and more especially on SNS activity in patients with T2DM.
2 CitationsSource
Abstract Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium...
158 CitationsSource
#1Anthony Markham (Springer Science+Business Media)H-Index: 12
#2Susan J. Keam (Springer Science+Business Media)H-Index: 6
Sotagliflozin (Zynquista鈩) is a dual inhibitor of sodium-glucose co-transporters (SGLT) 1 and 2 being developed by Lexicon Pharmaceuticals and Sanofi as a treatment for type 1 (T1DM) and type 2 diabetes mellitus (T2DM). The drug has a dual action, blunting and delaying absorption of glucose from the gastrointestinal tract and the reabsorption of glucose in the proximal tubule of the kidney, respectively. In the phase III inTandem clinical trial program in patients with T1DM, sotagliflozin as an ...
2 CitationsSource
Cited By0
#1Niki Katsiki (AHEPA University Hospital)H-Index: 4
#2Richard Ofori-Asenso (Monash University)H-Index: 19
Last. Mohsen Mazidi ('KCL': King's College London)H-Index: 1
view all 4 authors...